Abbott Laboratories SG&A Expenses 2010-2024 | ABT
Abbott Laboratories annual/quarterly sg&a expenses history and growth rate from 2010 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.
- Abbott Laboratories sg&a expenses for the quarter ending March 31, 2024 were $2.959B, a 7.13% increase year-over-year.
- Abbott Laboratories sg&a expenses for the twelve months ending March 31, 2024 were $11.146B, a 0.69% decline year-over-year.
- Abbott Laboratories annual sg&a expenses for 2023 were $10.949B, a 2.66% decline from 2022.
- Abbott Laboratories annual sg&a expenses for 2022 were $11.248B, a 0.67% decline from 2021.
- Abbott Laboratories annual sg&a expenses for 2021 were $11.324B, a 16.79% increase from 2020.
| Abbott Laboratories Annual SG&A Expenses (Millions of US $) |
|
|---|---|
| 2023 | $10,949 |
| 2022 | $11,248 |
| 2021 | $11,324 |
| 2020 | $9,696 |
| 2019 | $9,765 |
| 2018 | $9,744 |
| 2017 | $9,182 |
| 2016 | $6,736 |
| 2015 | $6,785 |
| 2014 | $6,530 |
| 2013 | $6,372 |
| 2012 | $6,735 |
| 2011 | $7,365 |
| 2010 | $10,376 |
| 2009 | $8,406 |
| Abbott Laboratories Quarterly SG&A Expenses (Millions of US $) |
|
|---|---|
| 2024-03-31 | $2,959 |
| 2023-12-31 | $2,724 |
| 2023-09-30 | $2,723 |
| 2023-06-30 | $2,740 |
| 2023-03-31 | $2,762 |
| 2022-12-31 | $2,973 |
| 2022-09-30 | $2,731 |
| 2022-06-30 | $2,757 |
| 2022-03-31 | $2,787 |
| 2021-12-31 | $3,048 |
| 2021-09-30 | $2,767 |
| 2021-06-30 | $2,726 |
| 2021-03-31 | $2,783 |
| 2020-12-31 | $2,570 |
| 2020-09-30 | $2,302 |
| 2020-06-30 | $2,276 |
| 2020-03-31 | $2,548 |
| 2019-12-31 | $2,413 |
| 2019-09-30 | $2,440 |
| 2019-06-30 | $2,434 |
| 2019-03-31 | $2,478 |
| 2018-12-31 | $2,359 |
| 2018-09-30 | $2,377 |
| 2018-06-30 | $2,466 |
| 2018-03-31 | $2,542 |
| 2017-12-31 | $2,477 |
| 2017-09-30 | $2,115 |
| 2017-06-30 | $2,150 |
| 2017-03-31 | $2,440 |
| 2016-12-31 | $1,673 |
| 2016-09-30 | $1,628 |
| 2016-06-30 | $1,737 |
| 2016-03-31 | $1,698 |
| 2015-12-31 | $1,655 |
| 2015-09-30 | $1,666 |
| 2015-06-30 | $1,727 |
| 2015-03-31 | $1,737 |
| 2014-12-31 | $1,666 |
| 2014-09-30 | $1,595 |
| 2014-06-30 | $1,649 |
| 2014-03-31 | $1,620 |
| 2013-12-31 | $1,260 |
| 2013-09-30 | $1,612 |
| 2013-06-30 | $1,714 |
| 2013-03-31 | $1,786 |
| 2012-12-31 | $1,159 |
| 2012-09-30 | $1,920 |
| 2012-06-30 | $1,814 |
| 2012-03-31 | $1,842 |
| 2011-12-31 | $2,905 |
| 2011-09-30 | $4,239 |
| 2011-06-30 | $2,762 |
| 2011-03-31 | $2,850 |
| 2010-12-31 | $2,797 |
| 2010-09-30 | $2,673 |
| 2010-06-30 | $2,743 |
| 2010-03-31 | $2,162 |
| 2009-12-31 | $2,225 |
| 2009-09-30 | $2,086 |
| 2009-06-30 | $2,024 |
| 2009-03-31 | $2,071 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $175.233B | $40.109B |
| Abbott Labs discovers, develops, manufactures & sells a diversified line of health care products. Established Pharmaceuticals Division includes branded generics business in the emerging markets. Medical Devices unit includes the diabetes care, vision care & vascular businesses. Diagnostics unit manufactures and markets diagnostic systems and tests in four business lines core laboratory, molecular, point of care and rapid diagnostics. Nutrition unit includes a broad line of pediatric and adult nutritional products. Abbott acquired CFR Pharmaceuticals, Tendyne Holdings, Inc., St. Jude Medical and Alere Inc. On the other hand, Abbott sold its developed markets branded generics pharmaceuticals business to Mylan. Abbott retained the branded generics pharmaceuticals business in emerging markets. Abbott sold its animal health business to Zoetis Inc and divested its vision care business, Medical Optics, to Johnson & Johnson. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stryker (SYK) | United States | $129.957B | 31.13 |
| Boston Scientific (BSX) | United States | $110.003B | 35.04 |
| Medtronic (MDT) | Ireland | $108.204B | 15.64 |
| EssilorLuxottica (ESLOY) | France | $99.874B | 0.00 |
| Lonza Group Ag (LZAGY) | Switzerland | $39.398B | 0.00 |
| Haleon (HLN) | United Kingdom | $38.127B | 27.83 |
| ResMed (RMD) | United States | $30.257B | 28.41 |
| Koninklijke Philips (PHG) | Netherlands | $25.296B | 19.60 |
| Terumo (TRUMY) | Japan | $25.163B | 35.54 |
| Zimmer Biomet Holdings (ZBH) | United States | $23.688B | 15.13 |
| Baxter (BAX) | United States | $16.913B | 12.02 |
| Insulet (PODD) | United States | $12.064B | 53.49 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $10.877B | 0.00 |
| Demant (WILYY) | Denmark | $10.259B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $8.130B | 26.59 |
| BellRing Brands (BRBR) | United States | $7.607B | 35.78 |
| Lantheus Holdings (LNTH) | United States | $5.529B | 13.78 |
| GN Store Nord (GNNDY) | Denmark | $4.717B | 26.49 |
| Haemonetics (HAE) | United States | $4.448B | 21.98 |
| Perrigo (PRGO) | Ireland | $3.708B | 11.24 |
| Envista Holdings (NVST) | United States | $3.128B | 12.91 |
| Prestige Consumer Healthcare (PBH) | United States | $3.126B | 14.87 |
| QuidelOrtho (QDEL) | United States | $2.927B | 16.25 |
| Neogen (NEOG) | United States | $2.853B | 27.44 |
| TG Therapeutics (TGTX) | United States | $2.528B | 71.13 |
| ICU Medical (ICUI) | United States | $2.464B | 21.75 |
| Green Thumb Industries (GTBIF) | United States | $2.303B | 45.62 |
| Maravai LifeSciences Holdings (MRVI) | United States | $2.250B | 0.00 |
| Agios Pharmaceuticals (AGIO) | United States | $2.157B | 0.00 |
| LeMaitre Vascular (LMAT) | United States | $1.765B | 51.74 |
| Warby Parker (WRBY) | United States | $1.662B | 0.00 |
| InMode (INMD) | Israel | $1.576B | 8.38 |
| Verano Holdings (VRNOF) | United States | $1.342B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.331B | 9.89 |
| Owens & Minor (OMI) | United States | $1.329B | 11.58 |
| National Vision Holdings (EYE) | United States | $1.113B | 35.42 |
| AtriCure (ATRC) | United States | $1.028B | 0.00 |
| BioLife Solutions (BLFS) | United States | $0.994B | 0.00 |
| Evolus (EOLS) | United States | $0.791B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $0.735B | 15.65 |
| Canopy Growth (CGC) | Canada | $0.714B | 0.00 |
| Quanterix (QTRX) | United States | $0.619B | 0.00 |
| Valneva SE (VALN) | France | $0.619B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.617B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.612B | 14.39 |
| Surmodics (SRDX) | United States | $0.600B | 37.59 |
| PetIQ (PETQ) | United States | $0.594B | 19.19 |
| Jin Medical (ZJYL) | China | $0.476B | 0.00 |
| ZimVie (ZIMV) | United States | $0.444B | 37.84 |
| TerrAscend (TSNDF) | Canada | $0.434B | 0.00 |
| Biote (BTMD) | United States | $0.417B | 9.60 |
| OraSure Technologies (OSUR) | United States | $0.346B | 11.14 |
| Aurora Cannabis (ACB) | Canada | $0.337B | 0.00 |
| Cerus (CERS) | United States | $0.325B | 0.00 |
| Zynex (ZYXI) | United States | $0.318B | 43.56 |
| Viemed Healthcare (VMD) | United States | $0.273B | 27.00 |
| Sanara MedTech (SMTI) | United States | $0.265B | 0.00 |
| MacroGenics (MGNX) | United States | $0.259B | 0.00 |
| Ayr Wellness (AYRWF) | United States | $0.241B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.240B | 15.11 |
| TriSalus Life Sciences (TLSI) | United States | $0.204B | 0.00 |
| Omeros (OMER) | United States | $0.191B | 0.00 |
| High Tide (HITI) | Canada | $0.189B | 0.00 |
| Organigram Holdings (OGI) | Canada | $0.179B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.178B | 0.00 |
| Eagleford Energy (GRUSF) | United States | $0.153B | 73.30 |
| Veru (VERU) | United States | $0.146B | 0.00 |
| InterCure (INCR) | Israel | $0.143B | 24.08 |
| FitLife Brands (FTLF) | United States | $0.142B | 20.13 |
| Quipt Home Medical (QIPT) | United States | $0.141B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.117B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.106B | 0.00 |
| Fonar (FONR) | United States | $0.097B | 8.30 |
| Brainsway (BWAY) | Israel | $0.094B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.089B | 0.00 |
| Chimerix (CMRX) | United States | $0.082B | 0.00 |
| MariMed (MRMD) | United States | $0.082B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.077B | 0.00 |
| Zevia PBC (ZVIA) | United States | $0.064B | 0.00 |
| Apyx Medical (APYX) | United States | $0.055B | 0.00 |
| Safety Shot (SHOT) | United States | $0.055B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.055B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.049B | 0.00 |
| Eagle Pharmaceuticals (EGRX) | United States | $0.043B | 2.83 |
| United-Guardian (UG) | United States | $0.042B | 15.25 |
| Bright Green (BGXX) | United States | $0.041B | 0.00 |
| ImmuCell (ICCC) | United States | $0.034B | 0.00 |
| Modular Medical (MODD) | United States | $0.034B | 0.00 |
| Exagen (XGN) | United States | $0.033B | 0.00 |
| Nephros (NEPH) | United States | $0.023B | 0.00 |
| Agape ATP (ATPC) | $0.020B | 0.00 | |
| Innovative Eyewear (LUCY) | United States | $0.017B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.016B | 0.00 |
| Flora Growth (FLGC) | United States | $0.016B | 0.00 |
| FSD PHARMA (HUGE) | Canada | $0.013B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.012B | 0.00 |
| GUARDION HEALTH (GHSI) | United States | $0.012B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.011B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.008B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.008B | 0.00 |
| Sharps Technology (STSS) | United States | $0.007B | 0.00 |
| Leafly Holdings (LFLY) | United States | $0.004B | 0.00 |
| Senestech (SNES) | United States | $0.004B | 0.00 |
| Lucy Scientific Discovery (LSDI) | Canada | $0.002B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.001B | 0.00 |
| Smart For Life (SMFL) | United States | $0.000B | 0.00 |
| Bruush Oral Care (BRSH) | $0.000B | 0.00 | |
| SNDL (SNDL) | Canada | $0.000B | 0.00 |